Results 11 to 20 of about 17,554 (214)

Design, optimization, and in vivo evaluation of invasome-mediated candesartan for the control of diabetes-associated atherosclerosis

Drug Delivery and Translational Research, 2023
Atherosclerosis is an inflammatory disease characterized by the accumulation of arterial plaque. Diabetes mellitus stands out as a major risk factor for atherosclerosis.
A. Fouad, Mohammed R A Ali, Demiana M. Naguib, H. Farouk, Mohamed I. Zanaty, F. A. El-Ela   +5 more
semanticscholar   +1 more source

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation

Experimental and Molecular Medicine, 2023
Insulin resistance is a major contributor to the pathogenesis of several human diseases, including type 2 diabetes, hypertension, and hyperlipidemia. Notably, insulin resistance and hypertension share common abnormalities, including increased oxidative ...
J. Lee, Hyun-Oh Gu, Yunshin Jung, Yun-Shin Jung, S. Seo, J. Hong, I. Hong, Dae Ho Lee, O. Kim, Byung-Chul Oh   +9 more
semanticscholar   +1 more source

Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials

International Journal of Stroke, 2023
Background: Cerebral microvascular dysfunction is commonly seen in Alzheimer’s disease (AD) and vascular cognitive impairment (VCI). Cerebrovascular reactivity (CVR) to CO2 reflects cerebral microvascular health and may be modulated by the renin ...
Brandon C. Henley, Maureen Okafor, A. Kulshreshtha, Antoine R Trammell, I. Hajjar   +4 more
semanticscholar   +1 more source

Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease

Brain Communications, 2022
Observational studies suggest that angiotensin receptor blockers in hypertensive adults are associated with lower post-mortem indicators of Alzheimer’s disease pathology.
I. Hajjar, Maureen Okafor, Limeng Wan, Zhiyi Yang, J. Nye, Anastasia Bohsali, L. Shaw, A. Levey, J. Lah, V. Calhoun, Reneé H Moore, F. Goldstein   +11 more
semanticscholar   +1 more source

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Proceedings of the National Academy of Sciences of the United States of America, 2021
Li et al. (1) recently report the discovery of 16 Food and Drug Administration – approved drugs as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) inhibitors. They were identified from a computational virtual screening
Chunlong Ma, Jun Wang
semanticscholar   +1 more source

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

Clinical science, 2021
The key link between renin–angiotensin system (RAS) and COVID-19 is ACE2 (angiotensin-converting enzyme 2), which acts as a double-edged sword, because ACE2 increases the tissue anti-inflammatory response but it is also the entry receptor for the virus ...
M. A. Pedrosa, Rita Valenzuela, Pablo F. Garrido, C. Labandeira, Gemma Navarro, R. Franco, J. Labandeira-Garcia, A. Rodriguez-Perez   +7 more
semanticscholar   +1 more source

Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity

Frontiers in Immunology, 2022
Aberrant activation of the NLRP3 inflammasome promotes the pathogenesis of many inflammatory diseases. The development of the NLRP3 inflammasome inhibitors from existing drugs for new therapeutic purposes is becoming more important.
Wen‐Yu Lin, Lan-hui Li, Y. Hsiao, Wei-Ting Wong, Hsiao-Wen Chiu, Hsien-Ta Hsu, Yi-Jen Peng, Chen-Lung Ho, O. Chernikov, Shu-Meng Cheng, S. Yang, Kuo-Feng Hua   +11 more
semanticscholar   +1 more source

Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine-induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway

Molecular Medicine Reports, 2022
Morphine is the most common drug of choice in clinical pain management; however, morphine tolerance presents a significant clinical challenge. The pathogenesis of morphine tolerance is known to be closely associated with angiotensin II receptor type 1 ...
Wenxin Zhao, Feiyan Shen, Jixiang Yao, Shanshan Su, Z. Zhao   +4 more
semanticscholar   +1 more source

Candesartan Reduces Neuronal Apoptosis Caused by Ischemic Stroke via Regulating the FFAR1/ITGA4 Pathway

Mediators of Inflammation, 2022
Ischemic stroke (IS) is a general term for necrosis of brain tissue caused by stenosis, occlusion of arteries supplying blood to the brain (carotid artery and vertebral artery), and insufficient blood supply to the brain.
Yuqing Ding, Yue Lang, Hui Zhang, Yu Li, Xiao Liu, Minjie Li   +5 more
semanticscholar   +1 more source

RETRACTED ARTICLE: Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1–7 Signals

Biological Trace Element Research, 2022
Cadmium (Cd) is a serious pollutant in the environment. Candesartan is an angiotensin II (Ang II) receptor antagonist with promising diverse health benefits.
E. Kamel, Wail M. Gad-Elrab, Mohammed A. Ahmed, Zuhair M. Mohammedsaleh, Emad H. M. Hassanein, Fares E. M. Ali   +5 more
semanticscholar   +1 more source